Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Investigation

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI44504PMID 21285512PMCID PMC3049366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

  2008cited by this paper
• p53 promoter selection: Choosing between life and death

  2008cited by this paper
• Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities

  2008cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

  2007cited by this paper
• Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development

  2007cited by this paper
• The oncogenic roles of p53 mutants in mouse models.

  2007cited by this paper
• p53 Induced Growth Arrest versus Apoptosis and its Modulation by Survival Cytokines

  2007cited by this paper
• Adenovirus p53 gene therapy

  2006cited by this paper
• Modeling the therapeutic efficacy of p53 restoration in tumors.

  2006cited by this paper
• Primary and Compensatory Roles for RB Family Members at Cell Cycle Gene Promoters That Are Deacetylated and Downregulated in Doxorubicin-Induced Senescence of Breast Cancer Cells

  2006cited by this paper
• Exploiting the p53 pathway for the diagnosis and therapy of human cancer.

  2005cited by this paper
• Comparative binding of p53 to its promoter and DNA recognition elements.

  2005cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004cited by this paper
• Intrinsic tumour suppression

  2004cited by this paper
• Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

  2004cited by this paper
• Gene Therapy Progress and Prospects: cancer gene therapy using tumour suppressor genes

  2004cited by this paper
• Cancer gene therapy: an awkward adolescence

  2003cited by this paper
• Why did p53 gene therapy fail in ovarian cancer?

  2003cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

  2002cited by this paper
• PUMA, a novel proapoptotic gene, is induced by p53.

  2001cited by this paper
• An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2

  2001cited by this paper
• Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo

  2001cited by this paper
• Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

  2001cited by this paper
• High metastatic potential in mice inheriting a targeted p53 missense mutation.

  2000cited by this paper
• A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer

  1998cited by this paper
• Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.

  1996cited by this paper
• Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

  1995cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper
• Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation.

  1995cited by this paper
• A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

  1995cited by this paper
• Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

  1994cited by this paper
• Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

  1994cited by this paper
• How loops, beta sheets, and alpha helices help us to understand p53.

  1994cited by this paper
• Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.

  1994cited by this paper
• How loops, β sheets, and α helices help us to understand p53

  1994cited by this paper
• Dosage‐dependent dominance over wild‐type p53 of a mutant p53 isolated from nasopharyngeal carcinoma 1

  1993cited by this paper
• THE P53 TUMOR SUPPRESSOR GENE

  1991cited by this paper
• Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

  1991cited by this paper
• Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

  1991cited by this paper

• Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair.

  2026cites this paper
• Design, synthesis and evaluation of benzodioxole and bromofuran tethered 1,2,4-triazole hybrids as potential anti breast cancer agents with computational insights

  2025cites this paper
• Dependence on Mdm2 for Mdm4 inhibition of p53 activity.

  2025cites this paper
• Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation

  2025cites this paper
• P53 and the Ultraviolet Radiation-Induced Skin Response: Finding the Light in the Darkness of Triggered Carcinogenesis

  2024cites this paper
• New potential targeted strategies in small cell lung cancer

  2023cites this paper
• Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis

  2023cites this paper
• TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia

  2023cites this paper
• Synonymous alterations of cancer-associated Trp53 CpG mutational hotspots cause fatal developmental jaw malocclusions but no tumors in knock-in mice

  2023cites this paper
• p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis

  2023cites this paper
• Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming

  2022cites this paper
• Co-Delivery of p53 Restored and E7 Targeted Nucleic Acids by Poly (Beta-Amino Ester) Complex Nanoparticles for the Treatment of HPV Related Cervical Lesions

  2022cites this paper
• Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD

  2022influential citation
• Druggable sites/pockets of the p53-DNAJA1 protein-protein interaction: In silico modeling and in vitro/in vivo validation.

  2022cites this paper
• Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

  2022cites this paper
• Partial p53 reactivation is sufficient to induce cancer regression

  2022cites this paper
• Differential gain-of-function activity of three p53 hotspot mutants in vivo.

  2022cites this paper
• Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma

  2022cites this paper
• Molecular Dynamic Simulations and Binding Free Energy Evaluations of Thiazolo-[2,3-b] Quinazolinone Derivatives With wtEGFR-TKD and "TMLR" Mutant EGFR-TKD

  2021cites this paper
• Myofibroblast senescence promotes arrhythmogenic remodeling in the aged infarcted rabbit heart

  2021cites this paper
• Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

  2021cites this paper
• TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

  2021cites this paper
• p53 partial loss-of-function mutations sensitize to chemotherapy

  2021cites this paper
• Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology

  2020cites this paper
• Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance

  2020cites this paper
• Tumor-specific genetic profiling and therapy in biomedicine

  2020cites this paper
• Sodium cantharidinate, a novel anti-pancreatic cancer agent that activates functional p53

  2020cites this paper
• Interplay between HMGA and TP53 in cell cycle control along tumor progression

  2020cites this paper
• p53 tetramerization: at the center of the dominant-negative effect of mutant p53

  2020cites this paper
• Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling

  2020cites this paper
• Expression of the long noncoding RNA DINO in HPV positive cervical cancer cells reactivates the dormant TP53 tumor suppressor through ATM/CHK2 signaling

  2020cites this paper
• The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment

  2020cites this paper
• Synthesis and anticancer activity of thiourea derivatives bearing a benzodioxole moiety with EGFR inhibitory activity, apoptosis assay and molecular docking study.

  2020cites this paper
• Insights from In Vivo Studies of Cellular Senescence

  2020cites this paper
• p53-dependent and -independent mechanisms of p53-targeting small molecules

  2020cites this paper
• Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors

  2019cites this paper
• The New Genetic Landscape of Cushing’s Disease: Deubiquitinases in the Spotlight

  2019cites this paper
• Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition

  2019cites this paper
• Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.

  2019cites this paper
• Do Mutations Turn p53 into an Oncogene?

  2019cites this paper
• CDK9 inhibitors reactivate p53 by downregulating iASPP.

  2019cites this paper
• Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo

  2019cites this paper
• Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses

  2019cites this paper
• Cancer therapeutic targeting using mutant–p53-specific siRNAs

  2019cites this paper
• Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity

  2019cites this paper
• Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.

  2019cites this paper
• Restoring p53 in cancer: the promises and the challenges

  2019cites this paper
• Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics

  2019cites this paper
• Développement d'un biosenseur fluorescent d'un mutant de p53 sujet à l'agrégation dans les cancers

  2019cites this paper
• Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes

  2018cites this paper
• Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma

  2018cites this paper
• Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration

  2018cites this paper
• How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.

  2018cites this paper
• Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells

  2018cites this paper
• Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

  2018cites this paper
• Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism

  2018cites this paper
• Tumor suppressive role for kinases phosphorylating p53 in DNA damage‐induced apoptosis

  2018cites this paper
• Role of p53 in the chronic pulmonary immune response to tangled or rod-like multi-walled carbon nanotubes

  2018cites this paper
• Молекулярно-генетический профиль плоскоклеточного рака головы и шеи

  2018cites this paper
• Mutant p53 in colon cancer

  2018cites this paper
• Spontaneous Cancers, But Not Many Induced Ones in Animals, Resemble Semi-New Organisms that Possess a Unique Programmed Cell Death Mode Different from Apoptosis, Senescent Death, Necrosis and Stress-Induced Cell Death

  2018cites this paper
• p53 mutation in colon cancer.

  2018cites this paper
• Gain-of-function and dominant-negative effects of distinct p53 mutations in lung tumours

  2018cites this paper
• Deconvolution of the immune landscape of cancer transcriptomics data, its relationship to patient survival and tumour subtypes

  2018cites this paper
• Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

  2018cites this paper
• New therapeutic strategies to treat human cancers expressing mutant p53 proteins

  2018cites this paper
• EVALUATING THE THERAPEUTIC EFFICACY OF RESTORING WILD-TYPE P53 ACTIVITY IN P53-MUTANT TUMORS

  2017influential citation
• Mutant p53 proteins alter signaling pathways involved in autophagy and redox regulation in cancer cells

  2017cites this paper
• Mutant p53 as a target for cancer treatment.

  2017cites this paper
• Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas

  2017cites this paper
• Nucleotide Excision Repair: From Neurodegeneration to Cancer.

  2017cites this paper
• Putting p53 in Context.

  2017cites this paper
• Still Laughing Failures behind the Windows of Cancer Therapeutic Strategies

  2017cites this paper
• Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity

  2017cites this paper
• Commentary on "Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents".

  2016cites this paper
• Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer

  2016cites this paper
• Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.

  2016cites this paper
• Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

  2016cites this paper
• Novel targets and interaction partners of mutant p53 Gain-Of-Function.

  2016cites this paper
• [6]‐Shogaol, a Novel Chemopreventor in 7,12‐Dimethylbenz[a]anthracene‐induced Hamster Buccal Pouch Carcinogenesis

  2016cites this paper
• The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.

  2016cites this paper
• miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53.

  2016cites this paper
• Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo

  2016cites this paper
• Natural Polyphenols in Cancer Chemoresistance

  2016cites this paper
• Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73

  2016cites this paper
• Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival

  2015cites this paper
• Structure- and Ligand-Based Virtual Screening Identifies New Scaffolds for Inhibitors of the Oncoprotein MDM2

  2015cites this paper
• Therapeutic targeting of tumor suppressor genes

  2015cites this paper
• Synthetic epigenetics—towards intelligent control of epigenetic states and cell identity

  2015cites this paper
• TP53: an oncogene in disguise

  2015influential citation
• The Contrived Mutant p53 Oncogene – Beyond Loss of Functions

  2015cites this paper
• Oncogenes and Tumor Suppressors Therapeutic Ef fi cacy of p 53 Restoration in Mdm 2-Overexpressing Tumors

  2015cites this paper
• Systemic Akt1 Deletion after Tumor Onset in p53(-/-) Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration.

  2015cites this paper
• IN VIVO SIGNIFICANCE OF THE MDM4 AND P73 INTERACTION DURING DEVELOPMENT AND TUMORIGENESIS

  2015cites this paper
• Therapeutic Nano- and Microparticles for Angiogenesis Dependent Diseases

  2015cites this paper
• BASIC AND TRANSLATIONAL — ALIMENTARY TRACT TRIM 59 Is Up-regulated in Gastric Tumors , Promoting Ubiquitination and Degradation of p 53

  2014cites this paper
• TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53.

  2014cites this paper
• Berberine and S allyl cysteine mediated amelioration of DEN+CCl4 induced hepatocarcinoma.

  2014cites this paper
• Circadian rhythms as novel chemotherapeutic strategies for breast cancer

  2014cites this paper
• Star-PAP controls HPV E 6 regulation of p 53 and sensitizes cells to VP-16

  2014cites this paper